

ICAGEN INC  
Form SC TO-T/A  
September 13, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**SCHEDULE TO**  
**TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR SECTION 13(E)(1)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**(Amendment No. 6)**

**ICAGEN, INC.**  
**(Name of Subject Company (Issuer))**

**PFIZER INC.**

**ECLIPSE ACQUISITION CORP.**  
**(Names of Filing Persons (Offerors))**

**Common Stock, par value \$0.001 per share**  
**(Title of Class of Securities)**

**45104P500**

Edgar Filing: ICAGEN INC - Form SC TO-T/A

(CUSIP Number of Common Stock)

**Amy W. Schulman**

**Executive Vice President and General Counsel**

**Pfizer Inc.**

**235 East 42<sup>nd</sup> Street**

**New York, New York 10017-5755**

**Telephone: (212) 733-2323**

(Name, address and telephone number of person authorized to receive notices and communications on behalf of filing persons)

*with copies to:*

**Steven A. Wilcox**

**Ropes & Gray LLP**

**Prudential Tower, 800 Boylston Street**

**Boston, MA 02199**

**Telephone: (617) 951-7000**

**CALCULATION OF FILING FEE**

**Transaction Valuation\***  
**\$49,563,006**

**Amount Of Filing Fee\*\***  
**\$5,754.26**

\* Estimated solely for purposes of calculating amount of filing fee in accordance with Rule 0-11 under the Securities Exchange Act of 1934. The transaction value was calculated by multiplying \$6.00, which is the purchase price in the Offer, by the number of outstanding shares of Common Stock (the Shares) of Icagen, Inc. (Icagen) as of July 20, 2011, which consists of 8,852,725 Shares issued and outstanding, 36,250 in-the-money options to purchase Shares and 438,541 Shares underlying restricted stock units, less 1,067,015 shares beneficially owned by Pfizer Inc.

\*\*

## Edgar Filing: ICAGEN INC - Form SC TO-T/A

The amount of filing fee is calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory No. 5 for fiscal year 2011 issued by the Securities and Exchange Commission. Such fee equals 0.011610% of the transaction value.

- Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number or the Form or Schedule and the date of its filing.

|                           |                |
|---------------------------|----------------|
| Amount Previously Paid:   | \$5,754.26     |
| Form or Registration No.: | Schedule TO-T  |
| Filing Party:             | Pfizer Inc.    |
| Date Filed:               | August 3, 2011 |

- Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. Check the appropriate boxes below to designate any transactions to which the statement relates:

- Third-party tender offer subject to Rule 14d-1.
- Issuer tender offer subject to Rule 13e-4.
- Going-private transaction subject to Rule 13e-3.
- Amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

- Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
- Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

This Amendment No. 6 to the Tender Offer Statement on Schedule TO (this *Amendment* ), filed with the Securities and Exchange Commission (the *SEC* ) on September 13, 2011, amends and supplements the Tender Offer Statement on Schedule TO filed on August 3, 2011, as amended by Amendment No. 1 filed with the SEC on August 19, 2011, Amendment No. 2 filed with the SEC on August 26, 2011, Amendment No. 3 filed with the SEC on September 1, 2011, Amendment No. 4 filed with the SEC on September 2, 2011, and Amendment No. 5 filed with the SEC on September 6, 2011 (as amended or supplemented from time to time, the *Schedule TO* ) and relates to a tender offer by Eclipse Acquisition Corp., a Delaware corporation (the *Purchaser* ) and a wholly owned subsidiary of Pfizer Inc., a Delaware corporation ( *Pfizer* ), to purchase all of the outstanding shares of Common Stock, par value \$0.001 per share (the *Shares* ), of Icagen, Inc., a Delaware corporation ( *Icagen* ), at a purchase price of \$6.00 per Share, paid to the seller in cash, without interest thereon, less any applicable withholding and transfer taxes, and subject to the conditions set forth in the Offer to Purchase dated August 3, 2011 (the *Offer to Purchase* ) and in the related Letter of Transmittal (the *Letter of Transmittal* ) which, together with the Offer to Purchase, as each may be amended and supplemented from time to time, constitute the *Offer* ). This Amendment is being filed on behalf of the Purchaser and Pfizer.

Except as otherwise set forth below, the information set forth in the Schedule TO remains unchanged and is incorporated herein by reference as relevant to the items in this Amendment.

### Items 1 through 9 and Item 11.

Items 1 through 9 and Item 11 of the Schedule TO are hereby amended and supplemented as follows:

On September 13, 2011, the Purchaser extended the expiration of the subsequent offering period of the Offer until 6:00 p.m., New York City time, on Monday, September 19, 2011. The subsequent offering period of the Offer was previously scheduled to expire at 6:00 p.m., New York City time, on Monday, September 12, 2011. The Depository has advised Pfizer that, as of 6:00 p.m., New York City time, on September 12, 2011, a total of approximately 5,094,558 shares of Icagen's common stock had been tendered, including shares tendered during the initial offering period and the subsequent offering period. Eclipse has accepted all such tendered shares for payment and is the beneficial owner of such shares. As a wholly-owned subsidiary of Pfizer, Eclipse shares the power to vote and dispose of the 5,094,558 Shares it beneficially owns with Pfizer, which represents 55.6% of the total number of Shares outstanding.<sup>1</sup>

In addition, Pfizer already owns 1,067,015 Shares of Icagen's common stock, which when added to the number of Shares validly tendered during the initial offering period and all Shares validly tendered during the subsequent offering period represents approximately 67.2% of the outstanding shares of Icagen. Eclipse will promptly pay for all shares accepted for payment in accordance with the terms of the tender offer. Pfizer has sole voting and dispositive power over 1,067,015 Shares and shared voting and dispositive power over 5,094,558 Shares.

The full text of the press release issued by Pfizer and Icagen on September 13, 2011 announcing the extension of the subsequent offering period is attached hereto as Exhibit (a)(5)(G) and is incorporated herein by reference.

### Item 12. EXHIBITS

The following is filed as an Exhibit to this Amendment:

(a)(5)(G) Joint Press Release issued by Pfizer Inc. and Icagen, Inc., dated September 13, 2011.

<sup>1</sup> Calculation based on 9,164,681 shares outstanding as of September 12, 2011, which figure is based on information provided by Icagen, Inc.'s transfer agent.

**SIGNATURES**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

PFIZER INC.

Dated: September 13, 2011

By: /s/ BRYAN A. SUPRAN  
Name: Bryan A. Supran  
Title: Senior Vice President and Associate General Counsel

ECLIPSE ACQUISITION CORP.

Dated: September 13, 2011

By: /s/ ANDREW MURATORE  
Name: Andrew Muratore  
Title: Vice President and Secretary

---

**EXHIBIT INDEX**

- (a)(1)(A) Offer to Purchase for Cash, dated August 3, 2011.\*
- (a)(1)(B) Form of Letter of Transmittal.\*
- (a)(1)(C) Form of Notice of Guaranteed Delivery.\*
- (a)(1)(D) Form of Letter to Brokers, Dealers, Banks, Trust Companies and Other Nominees.\*
- (a)(1)(E) Form of Letter to Clients for Use by Brokers, Dealers, Banks, Trust Companies and Other Nominees.\*
- (a)(2) None.
- (a)(3) None.
- (a)(4) None.
- (a)(5)(A) Joint Press Release issued by Pfizer Inc. and Icagen, Inc., dated July 20, 2011 (incorporated herein by reference to Exhibit 99.1 to the Schedule TO-C filed by Pfizer Inc. on July 20, 2011). \*
- (a)(5)(B) Summary Advertisement published in The Wall Street Journal on August 3, 2011. \*
- (a)(5)(C) Letter to the Board of Directors of Icagen, Inc., dated August 25, 2011.\*
- (a)(5)(D) Joint Press Release issued by Pfizer Inc. and Icagen, Inc., dated September 1, 2011. \*
- (a)(5)(E) Joint Press Release issued by Pfizer Inc. and Icagen, Inc., dated September 2, 2011. \*
- (a)(5)(F) Joint Press Release issued by Pfizer Inc. and Icagen, Inc., dated September 6, 2011. \*
- (a)(5)(G) Joint Press Release issued by Pfizer Inc. and Icagen, Inc., dated September 13, 2011.
- (b) None.
- (d)(1) Agreement and Plan of Merger, dated as of July 20, 2011, by and between Pfizer Inc., Eclipse Acquisition Corp., and Icagen, Inc. (incorporated herein by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Icagen, Inc. on July 20, 2011).\*
- (d)(2) Form of Tender and Voting Agreement, dated as of June 20, 2011, by and between Pfizer Inc., Icagen's directors and executive officers and Venrock Associates and Venrock Associates II, L.P.\*
- (d)(3) Amended and Restated Letter Agreement, dated October 10, 2006, by and between Pfizer Inc. and Icagen, Inc.\*
- (d)(4) Amendment to Amended and Restated Letter Agreement, dated June 14, 2011, by and between Pfizer Inc. and Icagen, Inc.\*
- (d)(5) Collaborative Research and License Agreement, dated as of August 13, 2007, between Icagen, Inc. and Pfizer Inc. (incorporated herein by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed by Icagen, Inc. on November 5, 2007).\*
- (d)(6) Agreement and Amendment to the Exclusive License Agreement, dated as of September 17, 2009, between Icagen, Inc. and Pfizer Inc. (incorporated herein by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed by Icagen, Inc. on November 9, 2009).\*
- (d)(7) Second Agreement and Amendment to the Exclusive License Agreement, dated as of September 21, 2010, between Icagen, Inc. and Pfizer Inc. (incorporated herein by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed by Icagen, Inc. on November 10, 2010).\*
- (d)(8) Third Agreement and Amendment to the Collaborative Research and License Agreement, dated July 20, 2011, between Icagen, Inc. and Pfizer Inc. (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by Icagen, Inc. on July 20, 2011).\*
- (d)(9) Purchase Agreement, dated August 13, 2007, between Icagen, Inc. and Pfizer Inc. (incorporated herein by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Icagen, Inc. on August 14, 2007).\*

- (d)(10) First Amendment to the Purchase Agreement, dated as of July 20, 2011, between Icagen, Inc. and Pfizer Inc. (incorporated herein by reference to Exhibit 4.2 to the Current Report on Form 8-K filed by Icagen, Inc. on July 20, 2011).\*
- (g) None.
- (h) None.

\* Previously filed.